These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14594556)

  • 1. Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines.
    Moldoveanu E; Moicean A; Vidulescu C; Marta D; Colita A
    J Cell Mol Med; 2003; 7(3):313-21. PubMed ID: 14594556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
    Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
    Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins.
    Parker JE; Fishlock KL; Mijovic A; Czepulkowski B; Pagliuca A; Mufti GJ
    Br J Haematol; 1998 Dec; 103(4):1075-82. PubMed ID: 9886323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
    Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
    Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
    Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression.
    Davis RE; Greenberg PL
    Leuk Res; 1998 Sep; 22(9):767-77. PubMed ID: 9716007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
    Zhang Z; Xie J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.
    Gorombei P; Guidez F; Ganesan S; Chiquet M; Pellagatti A; Goursaud L; Tekin N; Beurlet S; Patel S; Guerenne L; Le Pogam C; Setterblad N; de la Grange P; LeBoeuf C; Janin A; Noguera ME; Sarda-Mantel L; Merlet P; Boultwood J; Konopleva M; Andreeff M; West R; Pla M; Adès L; Fenaux P; Krief P; Chomienne C; Omidvar N; Padua RA
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes.
    Merchant SH; Gonchoroff NJ; Hutchison RE
    Cytometry; 2001 Feb; 46(1):28-32. PubMed ID: 11241504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
    Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V
    Clin Cancer Res; 2012 Jun; 18(11):3079-89. PubMed ID: 22496271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes.
    Boudard D; Vasselon C; Berthéas MF; Jaubert J; Mounier C; Reynaud J; Viallet A; Chautard S; Guyotat D; Campos L
    Am J Hematol; 2002 Jun; 70(2):115-25. PubMed ID: 12111784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment.
    Bogdanović AD; Trpinac DP; Janković GM; Bumbasirević VZ; Obradović M; Colović MD
    Leukemia; 1997 May; 11(5):656-9. PubMed ID: 9180288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro.
    Bouscary D; Chen YL; Guesnu M; Picard F; Viguier F; Lacombe C; Dreyfus F; Fontenay-Roupie M
    Exp Hematol; 2000 Jul; 28(7):784-91. PubMed ID: 10907640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
    Le Pogam C; Krief P; Beurlet S; Soulié A; Balitrand N; Cassinat B; Cavé H; Kosmider O; Setterblad N; Leboeuf C; Sarda-Mantel L; Hervatin F; Merlet P; Noguera ME; Janin A; Pla M; Fontenay M; Adès L; Fenaux P; Chomienne C; Padua RA; Omidvar N
    Leuk Res; 2013 Mar; 37(3):312-9. PubMed ID: 23153525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
    Jilg S; Reidel V; Müller-Thomas C; König J; Schauwecker J; Höckendorf U; Huberle C; Gorka O; Schmidt B; Burgkart R; Ruland J; Kolb HJ; Peschel C; Oostendorp RA; Götze KS; Jost PJ
    Leukemia; 2016 Jan; 30(1):112-23. PubMed ID: 26153654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expressions of survivin, Bcl-2 and VEGF in patients with myelodysplastic syndrome and their relationship].
    Sun H; Ma J; Sun L; Liu LX; Zhao LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):271-5. PubMed ID: 16638195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.